Over the last few decades, primary percutaneous coronary intervention (PCI) has revolutionised the treatment of ST-elevation myocardial infarction (STEMI) with rapid recanalisation of the infarct-related epicardial vessel, resulting in smaller infarct size and a substantial reduction in adverse clinical endpoints.
Over the last few decades, primary percutaneous coronary intervention (PCI) has revolutionised the treatment of ST-elevation myocardial infarction (STEMI) with rapid recanalisation of the infarct-related epicardial vessel, resulting in smaller infarct size and a substantial reduction in adverse clinical endpoints. 1, 2 However, suboptimal myocardial reperfusion is documented to occur in a relatively large proportion of patients undergoing primary PCI for STEMI, despite optimal restoration of epicardial flow, with unfavourable short-and long-term outcomes. 3 STEMI patients are at particularly high risk of thrombus embolisation due to elevated thrombotic burden and prothrombotic milieu. 4 Thrombus embolisation, either spontaneously or as a consequence of instrumentation, is associated with reduced levels of procedural success. While this is most commonly related to embolisation into the distal coronary tree, it also includes retrograde embolisation either into non-culprit vessels or systemic emboli, which could further complicate primary PCI.
Distal embolisation can lead to re-occlusion of the culprit vessel or its downstream branches and is a major contributor to slow and no re-flow by occlusion of distal microvasculature, leading to ongoing ischaemia despite a patent epicardial artery. Thereby, evidence of distal embolisation is quantified by thrombolysis in MI (TIMI) flow, myocardial blush grade and ST segment resolution. While angiographic signs of distal embolisation occur in 6-18% of cases of primary PCI in STEMI, [5] [6] [7] [8] [9] [10] [11] the true incidence may be much higher, demonstrated by retrieval of visible debris in up to 73% patients in studies such as the Enhanced
Myocardial Efficacy and Recovery by Aspiration of Liberated Debris
(EMERALD) trial. 12 Thrombus embolisation is associated with adverse procedural results and a greater frequency of adverse outcomes, including larger infarct size, reduced left ventricular ejection fraction, larger enzyme rises and increased rates of recurrent MI and mortality. 5, 6, 13 A high thrombus burden has been associated with incidence of distal embolisation and in itself is associated with PCI failure and adverse outcome in STEMI. [14] [15] [16] Due to the prognostic implication of thrombus embolisation, management of lesions with high thrombotic burden remains a challenge in the setting of primary PCI for STEMI.
Case
A 49-year-old man presented with a history of chest pain and worsening breathlessness over the previous 3 days. He A standard workhorse wire was taken to the distal LAD with no restoration of flow. A 2.5 × 15 mm balloon was inflated at the site of occlusion ( Figure 1B) . The next image showed retrograde thrombus embolisation into a large obtuse marginal branch ( Figure 1C ). This was accompanied by a drop in blood pressure requiring IV metaraminol and rapid deterioration to pulseless electrical activity (PEA) arrest.
Cardiopulmonary resuscitation was initiated, an AutoPulse ® device applied, and the patient was intubated. A second wire was passed to the circumflex vessel and after predilatation a 3.0 × 28 mm drugeluting stent (DES) was deployed with a further 3.0 × 38 mm DES deployed in the LAD. Despite TIMI 3 flow in both vessels ( Figure 1D ), there was no return of spontaneous circulation and resuscitation was discontinued after 38 cycles of CPR. supportive measures, such as use of mechanical support either upfront due to the large area of myocardium at risk or at the point of thrombus embolisation; however, these can often be overlooked with the need for rapid restoration of TIMI 3 flow in the culprit vessel.
Thrombus embolisation, both distal and retrograde, is associated with increased morbidity and mortality in primary PCI and its management is still debated. Here we review current data for pharmacological and interventional strategies to prevent thrombus embolisation and suggest an optimal therapeutic strategy in the setting of large thrombus burden in primary PCI.
Angiographic Predictors of Thrombus Embolisation in Primary PCI
The main predictor of embolisation is thrombus burden. Thrombus burden may be classified angiographically using the TIMI thrombus grade in Table 1 . 17 Since there is a high incidence of coronary occlusion in STEMI and large thrombus burden, in this setting thrombus grade 5 is reclassified after wire crossing and balloon passage/inflation. 14 Other predictors of embolisation include thrombus composition, TIMI flow, lesion length and large vessel diameter. [5] [6] [7] 18 The anatomical risk of embolisation should also be assessed before deciding on therapeutic 
Glycoprotein Inhibitors
Despite some evidence to suggest that adjunctive administration of GPIIb/IIIa inhibitors in STEMI may reduce mortality and re-infarction 23 there is no evidence to suggest benefit over risk of bleeding with routine facilitated use of GPIIb/IIIa inhibitors in STEMI. [24] [25] [26] [27] [28] Although initial non-randomised trials suggested benefit of localised intracoronary delivery of GPIIb/IIIa inhibitor over intravenous delivery in terms of TIMI flow and short-term mortality, no overall mortality benefit has been demonstrated. 29 There also appears to be a signal for use of 
angiographic evidence of large thrombus, slow-or no-reflow, and other thrombotic complications. It is important to note that this strategy has not yet been tested in randomised trials.
Anticoagulant Therapy
While there has been no randomised trial assessing unfractionated intraprocedural heparin in primary PCI there is a substantial body of experience and its use is recommended in current guidance (I/C). 19 There have been some randomised trials evaluating bivalirudin in the setting of STEMI with a recent meta-analysis demonstrating no mortality advantage and concerns over excess rates of early stent thrombosis in the bivalirudin treated arms. 25, [33] [34] [35] [36] [37] Further, the most recent large randomised study on the impact of bivalirudin during primary PCI trial where the Angiojet was tested in a cohort with large thrombus burden showed significant improvements in ST segment resolution, and 6-month major adverse cardiac event despite no difference in infarct size. 45 A meta-analysis of mechanical thrombectomy in STEMI showed no improvement in reperfusion or mortality despite a benefit in ST segment resolution. 46 Most of the current available thrombectomy data pertains to manual thrombus aspiration using the Export ® Aspiration Catheter (Medtronic) or the Diver ® (Invatec). These devices are simpler to use compared to mechanical devices. However, they are limited by the inability to aspirate large amounts of thrombus rendering them theoretically less effective in reducing thrombus load.
Manual thrombectomy devices have shown benefits compared with standard primary PCI using surrogate endpoints, such as TIMI flow, ST segment resolution, myocardial blush grade, infarct size and LV function. 47 However, evidence regarding clinical endpoints such as re-infarction, mortality and MACE as well as concerns regarding safety have meant that current guidance has downgraded the use of routine thrombectomy from recommended (IIa/B) to not recommended (III/A). 19 The Thrombus Aspiration during Percutaneous coronary intervention in Acute MI Study (TAPAS) trial, where more than 1,000 STEMI patients were randomised to either routine thrombus aspiration (Export Aspiration Catheter) or conventional primary PCI, showed significant improvement in myocardial blush grade and ST segment resolution as well as increased 1-year survival.
9 49, 51 Importantly, TOTAL showed a clear safety signal with an increase in incidence of stroke at 1 year in the thrombectomy arm compared with primary PCI alone. 52 The mechanism of this is presumed to be proximal or systemic embolisation of thrombus via the extraction of the device and it is therefore recommended that the guide be deeply engaged into the coronary ostium during thrombus aspiration and device removal as a preventative strategy; alternatively, a guide catheter extension may be used.
A recent meta-analysis combined data from 18,306 patients from the TAPAS, TASTE and TOTAL trials showed overall no differences between the two treatment groups in terms of mortality at 30 days, or incidence of stroke. 53 Subgroup analysis demonstrated that in patients with the highest thrombus burden defined by TIMI thrombus grade ≥3 there were fewer cardiovascular deaths as well; however, this group also had increased incidence of stroke/transient ischaemic attack; this could suggest that if systemic embolisation could be prevented then benefit could be seen in this high thrombus burden subgroup of patients.
Taken together, this would suggest that patients with a high thrombus burden benefit the most from thrombectomy by reducing the incidence of distal embolisation. Current guidelines have suggested that while routine thrombus aspiration is not recommended, it may be considered in specific cases where there is a high thrombus burden and risk of embolisation. 19 Innovations in device technology should now focus on mitigating risk of systemic embolisation and stroke during thrombectomy. Further trials are required to evaluate the utility and benefit of thrombus aspiration in cohorts with large thrombus burden; however, this would require large patient numbers to be powered to detect differences in hard clinical outcomes.
Embolic Protection Devices
Embolic protection devices include both proximal and distal devices. FilterWire EZ or conventional primary PCI. 55 An analysis of all trials of distal protection devices involving 1,353 patients showed that while there was some benefit in terms of myocardial blush grade there was no improvement in 30-day mortality. 56 The only studied proximal protection device is the Proxis Embolic Protection System (Velocimed) which theoretically confers complete protection from distal embolisation by deployment proximal to the lesion interrupting antegrade flow and therefore has the benefit of protecting all distal branches while thrombus is aspirated. The PRoximal Embolic Protection in Acute MI and Resolution of ST-Elevation trial, the only trial to date evaluating this device in STEMI, showed no benefit conferred in either surrogate or clinical outcomes. 57 Considering the paucity of data for embolic protection devices, they have not been recommended in current practice guidelines.
Excimer Laser Coronary Atherectomy
Excimer laser coronary atherectomy (ELCA) is potentially effective in reducing the size of coronary thrombus by inducing shock waves that can separate thrombus from the vessel wall, dissolve clot by acoustic waves within the thrombus structure and vaporise procoagulant mediators. 58, 59 Laser also has an inhibitory effect on platelet aggregation due to interaction with the 308-nm ultraviolet beam leading to 'stunned platelet phenomenon'. 60 Despite the theoretical potential, there are limited data to support its use in primary PCI.
The Cohort of Acute Revascularization of Myocardial infarction with
Excimer Laser (CARMEL) multicentre registry, enrolled 151 AMI patients, 65% of whom had large thrombus burden in the culprit artery who gained most benefit. 61 hours after the index procedure had no effect on a composite clinical outcome of mortality and revascularisation of non-culprit vessels. However, it did demonstrate a higher rate of target vessel revascularisation. 74 On the basis of the available data, deferred stenting is not recommended in the current guidelines (III/A).
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Therapeutic Strategy for Prevention of Thrombus Embolisation in Primary PCI
There is conflicting evidence as to the ideal management strategy in cases of large thrombus burden in STEMI. Based on the evidence presented here we propose an interventional algorithm in these cases 
Conclusion
Large thrombus burden in STEMI can further complicate primary PCI due to spontaneous or mechanical embolisation, either distally or retrograde, into a non-culprit vessel or systemically. In the context of no proven recommendation in this setting, we discuss some adjunctive and preventative pharmacological and interventional strategies and propose a management algorithm in the primary PCI setting. 
